期刊文献+

2012年南阳市疑似预防接种异常反应监测数据分析 被引量:2

Analysis of adverse events following immunization surveillance in Nanyang of 2012
下载PDF
导出
摘要 目的:评价2012年南阳市疑似预防接种异常反应(adverse event following immunization,AEFI)监测系统运转情况,探讨监测重点。方法:对2012年南阳市系统上报告的AEFI个案数据进行描述性流行病学分析。结果:2012年南阳市共报告127例个案,其中8个县报告例数不到10例,占61.54%;男性多于女性,性别比为1.89∶1;<1岁年龄组最多,占53.54%;一般反应占98.42%,异常反应占1.57%;百白破疫苗报告例数最多,占51.18%;白破疫苗AEFI发生率最高,为110.24/100万剂;接种后24 h内发生者101例,占79.53%;48 h内报告率和调查率均为100%。结论:全市AEFI监测敏感性尚需提高,低龄儿童、接种后2 d内为监测重点。 Objective : To evaluate the performance of adverse event following immunization (AEFI)and find the key problem of surveillance system in Nanyang in 2012. Methods: AEFI data from system reported by Nanyang city in 2012 was analyzed by the descriptive epidemiology method. Results: 127 AEFI cases were totally reported in Nanyang in 2012. The reported cases in 8 coun- ties were bellow 10, accounting for 61.54%. More cases occurred in males than females with the ratio of 1.89: 1. Cases aged 〈 1 year were the most, common accounting for 53.54%. 98.42% were presented general reactions after immunization, and 1.57% were rare, serious reactions. 51.18% were caused by the immunization of Diphtheria, Tetanus and Pertussis Combined Vac- cine, Absorbed(DPT). The highest rate was estimated 110.24/1 000 000 caused by Diphtheria and Tetanus Combined Vaccine(DT). 101 cases occurred within 24 h after vaccination, account- ing for 79.53%. The reported rate and the investigated rate within 48 h were all 100%. Conclu- sion: The sensitivity of Nanyang AEFI surveillance should be improved. Y'oung children within 2 days after vaccination are the focus of the AEFI surveillance.
出处 《河南医学研究》 CAS 2014年第2期137-140,共4页 Henan Medical Research
关键词 南阳市 疑似预防接种异常反应 监测 Nanyang city adverse events following immunization surveillance
  • 相关文献

参考文献4

二级参考文献21

  • 1郭飚,曹雷,曹玲生,徐立君,梁晓峰,张振国,罗耀星,孙印旗,彭国文,赵占杰.河北、广东省预防接种副反应监测试点培训效果评估[J].中国计划免疫,2005,11(4):302-305. 被引量:34
  • 2庄菱,郭飚,刘大卫,曹玲生,曹雷.全国预防接种异常反应监测省级师资培训效果评估[J].中国计划免疫,2006,12(3):218-220. 被引量:9
  • 3WHO/Immunization Vaccines and Biologicals(IVB). Joint Medical Products Assessment Tools of National Regulatory System Vaccines Assessment[S]. Geneva, Switzerland, 2004.
  • 4WHO&WPRO. Immunization safety surveillance:guidelines for managers of immunization programmes on reporting and investigating adverse events following immunization[S]. Manila, Philiodines. 1999.
  • 5国家统计局.2009年中国统计年鉴[M].北京:中国统计出版社,2009.
  • 6Weigong Zhou, Vitali Pool, John K, et al. Surveillance for Safety After Immunization:Vaccine Adverse Event Reporting System (VAERS)- United States, 1991-2001 [J]. MMWR, 2003, 52 (No.SS-1): 1-24.
  • 7卫生部.《2009年秋冬季甲型H1N1流感疫苗预防接种指导意见》[S].2009.
  • 8WHO&WPRO.Immunization safety surveillance: guidelines for managers of immunization pragrammes on reporting and investigating adverse events following immunization[S]. Manila, Philippines, 1999.
  • 9PAHO/WHO, Immunization safety: How to address events allegedly attribute to vaeeination or immunization[S], Washington, DC, US, 2002.
  • 10SE Tarvin, S Ballinger. Henoch-Schonlein purpura[J].Current Paediatrics, 2006, 16:259-263.

共引文献302

同被引文献27

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部